Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
NPCE
#2547
Neuropace, Inc. Common Stock
14.580
0
-0.95%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-0.95%
Monatliche Änderung
-9.97%
6 month change
+37.81%
Jahresänderung
+37.81%
Vorheriger Schlusskurs
14.720
0
Open
14.580
0
Bid
Ask
Low
14.580
0
High
14.580
0
Volumen
30
Märkte
Aktien
Gesundheitswesen
NPCE
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
24.47 M
25.1 M
28.34 M
32.56 M
—
Valuation ratios
Enterprise value
227.48 M
29.54 M
259.15 M
350.92 M
1.4 B
Price to earnings ratio
-4.65
-0.75
-7.7
-12.03
-54.54
Price to sales ratio
3.71
0.78
3.86
4.08
15.61
Price to cash flow ratio
-6.81
-0.96
-12.83
-18.16
-79.39
Price to book ratio
2.28
1.02
12.24
40.67
58.01
Enterprise value to EBITDA ratio
-9.82
-0.73
-9.71
-16.52
-72.34
Profitability ratios
Return on assets %
0.27
0.41
0.31
0.29
0.23
Return on equity %
0.49
1.35
1.6
3.39
1.56
Return on invested capital %
1 195.31
1 140.71
494.27
416.78
—
Gross margin %
74
71.38
73.56
73.94
306.88
Operating margin %
52.54
89.62
41.54
27.12
78.39
EBITDA margin %
-51.28
-88.39
-40.8
-26.58
-76.65
Net margin %
79.85
103.43
50.38
33.97
103.27
Liquidity ratios
Quick ratio
13.44
8.02
5.02
4.48
18.64
Current ratio
14.28
8.9
5.71
5.37
22.33
Inventory turnover
1.5
1.49
1.65
1.69
1.52
Asset turnover
0.34
0.37
0.59
0.79
0.92
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
0.37
0.46
0.53
0.63
2.27
Long term debt to total equity ratio
0.68
1.52
2.76
7.43
16.08
Per share metrics
Operating cash flow per share
1.48
1.5
0.76
0.61
0.52
EBIT per share
-1.43
-1.66
-1.05
-0.74
-0.58
EBITDA per share
-1.4
-1.64
-1.03
-0.73
-0.56
Total debt per share
—
—
—
—
—
Cash per share
6.96
3.15
2.57
1.81
7.62
Net current asset value per share
8
3.97
3.59
2.79
11.62
Tangible book value per share
4.43
1.41
0.8
0.28
2.2
Working capital per share
7.44
3.53
2.96
2.27
9.52
Book value per share
4.43
1.41
0.8
0.28
2.2
Nachrichten
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
NeuroPace: Leerink Partners hebt Kursziel auf 20 US-Dollar an/n
NeuroPace stock price target raised to $20 from $19 at Leerink Partners
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeuroPace-Aktie steigt nach starkem Q4-Umsatz und bestätigter UBS-Kaufempfehlung/n
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue
NeuroPace meldet 25 % Umsatzwachstum für 2025 und prognostiziert stetiges Wachstum
NeuroPace reports 25% revenue growth for 2025, projects steady growth